• Use the keyword text box above to search across all volumes for abstracts and authors.
  • You can filter the results by adjusting the search options under 'filter search results'.
  • Use the advanced search options to limit or expand the scope of the results found.

Showing page 1 of results 1 - 6 of about 6 pages

100% match
3 hit(s)
HTML
39kb

Burosumab Resulted in Better Clinical Outcomes Than Continuation with Conventional Therapy in Both Younger (1-4 Years-Old) and Older (5-12 Years-Old) Children with X-Linked Hypophosphatemia | ESPE2019
Wolfgang Högler; Erik A. Imel; Michael P. Whyte; Craig Munns; Anthony A. Portale; Leanne Ward; Ola Nilsson; Jill H. Simmons; Ra
http://abstracts.eurospe.org/hrp/0092/hrp0092RFC2.1
Published: 2019-08-22

100% match
3 hit(s)
HTML
37kb

Benefits of Long-Term Burosumab Persist in 11 Girls with X-Linked Hypophosphatemia (XLH) Who Transitioned into Adolescence During the Phase 2 CL201 Trial | ESPE2019
Annemieke Boot; Thomas O. Carpenter; Wolfgang Högler; Erik A. Imel; Anthony A. Portale; Agnès Linglart; Raja Padidela; Hoff Wi
http://abstracts.eurospe.org/hrp/0092/hrp0092FC2.2
Published: 2019-08-22

100% match
3 hit(s)
HTML
37kb

Continued Improvement in Clinical Outcomes with Burosumab, a Fully Human Anti-FGF23 Monoclonal Antibody: Results from a 3-Year, Phase 2, Clinical Trial in Children with X-Linked Hypophosphatemia (XLH) | ESPE2019
Agnès Linglart; Thomas O. Carpenter; Wolfgang Högler; Erik A. Imel; Anthony A. Portale; Annemieke Boot; Raja Padidela; Hoff Wi
http://abstracts.eurospe.org/hrp/0092/hrp0092FC2.1
Published: 2019-08-22

100% match
3 hit(s)
HTML
39kb

Burosumab Resulted in Better Clinical Outcomes Than Continuation with Conventional Therapy in Both Younger (1-4 Years-Old) and Older (5-12 Years-Old) Children with X-Linked Hypophosphatemia | ESPE2019
Wolfgang Högler; Erik A. Imel; Michael P. Whyte; Craig Munns; Anthony A. Portale; Leanne Ward; Ola Nilsson; Jill H. Simmons; Ra
http://abstracts.eurospe.org/hrp/0092/hrp0092rfc2.1.html
Published: 2019-08-22

100% match
3 hit(s)
HTML
37kb

Benefits of Long-Term Burosumab Persist in 11 Girls with X-Linked Hypophosphatemia (XLH) Who Transitioned into Adolescence During the Phase 2 CL201 Trial | ESPE2019
Annemieke Boot; Thomas O. Carpenter; Wolfgang Högler; Erik A. Imel; Anthony A. Portale; Agnès Linglart; Raja Padidela; Hoff Wi
http://abstracts.eurospe.org/hrp/0092/hrp0092fc2.2.html
Published: 2019-08-22

100% match
3 hit(s)
HTML
37kb

Continued Improvement in Clinical Outcomes with Burosumab, a Fully Human Anti-FGF23 Monoclonal Antibody: Results from a 3-Year, Phase 2, Clinical Trial in Children with X-Linked Hypophosphatemia (XLH) | ESPE2019
Agnès Linglart; Thomas O. Carpenter; Wolfgang Högler; Erik A. Imel; Anthony A. Portale; Annemieke Boot; Raja Padidela; Hoff Wi
http://abstracts.eurospe.org/hrp/0092/hrp0092fc2.1.html
Published: 2019-08-22

Filter search results





Publication date between
 and

Sort results by

Search for:

Similarity to search phrase (e.g. jones matches james):

My recent searches

San Martin Javier (<1 min ago)

My recently viewed abstracts

No recent abstracts.